{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,21]],"date-time":"2026-06-21T08:48:40Z","timestamp":1782031720642,"version":"3.54.5"},"reference-count":34,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","redjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Radiation Oncology*Biology*Physics"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.ijrobp.2025.01.031","type":"journal-article","created":{"date-parts":[[2025,2,7]],"date-time":"2025-02-07T11:19:23Z","timestamp":1738927163000},"page":"102-111","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["The Impact of Ultracentral Tumor Location on Outcomes in Patients with Pulmonary Oligometastases: A Secondary Analysis of the Single-Arm Phase 2 SABR-5 Trial"],"prefix":"10.1016","volume":"125","author":[{"given":"Sarah","family":"Baker","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Curtis","family":"Leclerc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanna","family":"Atmanspacher-Wirth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yizhou","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Devin","family":"Schellenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haley","family":"Clark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Mou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitchell","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fred","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanya","family":"Berrang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siavash","family":"Atrchian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alanah","family":"Bergman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nick","family":"Chng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quinn","family":"Matthews","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jee Suk","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Tyldesley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Olson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijrobp.2025.01.031_bib0001","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1200\/JCO.1995.13.1.8","article-title":"Oligometastases","volume":"13","author":"Hellman","year":"1995","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2025.01.031_bib0002","doi-asserted-by":"crossref","first-page":"570","DOI":"10.18632\/oncotarget.2677","article-title":"The landscape of metastatic progression patterns across major human cancers","volume":"6","author":"Budczies","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.ijrobp.2025.01.031_bib0003","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/S0039-6109(05)70204-8","article-title":"Secondary pulmonary malignancy","volume":"80","author":"Greelish","year":"2000","journal-title":"Surg Clin North Am"},{"key":"10.1016\/j.ijrobp.2025.01.031_bib0004","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.thorsurg.2005.12.003","article-title":"The molecular biology of pulmonary metastasis","volume":"16","author":"Krishnan","year":"2006","journal-title":"Thorac Surg Clin"},{"key":"10.1016\/j.ijrobp.2025.01.031_bib0005","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1200\/JGO.2015.002089","article-title":"Pulmonary nodules in patients with nonpulmonary cancer: Not always metastases","volume":"2","author":"Caparica","year":"2016","journal-title":"J Glob Oncol"},{"key":"10.1016\/j.ijrobp.2025.01.031_bib0006","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1001\/jamaoncol.2022.4394","article-title":"Treatment with stereotactic ablative radiotherapy for up to 5 oligometastases in patients with cancer: Primary toxic effect results of the nonrandomized phase 2 SABR-5 clinical trial","volume":"8","author":"Olson","year":"2022","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ijrobp.2025.01.031_bib0007","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1200\/JCO.18.00622","article-title":"Safety and efficacy of a five-fraction stereotactic body radiotherapy schedule for centrally located non-small-cell lung cancer: NRG oncology\/RTOG 0813 trial","volume":"37","author":"Bezjak","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2025.01.031_bib0008","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2023.109848","article-title":"Ten years outcomes after SABR in central and ultracentral primary lung tumors","volume":"188","author":"Tekatli","year":"2023","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2025.01.031_bib0009","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2023.107284","article-title":"Stereotactic body radiotherapy for lung oligo-metastases: Systematic review and International Stereotactic Radiosurgery Society Practice guidelines","volume":"182","author":"Mayinger","year":"2023","journal-title":"Lung Cancer"},{"key":"10.1016\/j.ijrobp.2025.01.031_bib0010","doi-asserted-by":"crossref","first-page":"4833","DOI":"10.1200\/JCO.2006.07.5937","article-title":"Excessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy for medically inoperable early-stage lung cancer","volume":"24","author":"Timmerman","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2025.01.031_bib0011","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/j.ijrobp.2024.03.050","article-title":"Stereotactic radiation for ultra-central non-small cell lung cancer: A safety and efficacy trial (SUNSET)","volume":"120","author":"Giuliani","year":"2024","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2025.01.031_bib0012","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1016\/j.jtho.2024.05.366","article-title":"Stereotactic body radiotherapy for centrally located inoperable early-stage NSCLC: EORTC 22113-08113 LungTech phase II trial results","volume":"19","author":"Levy","year":"2024","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ijrobp.2025.01.031_bib0013","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1016\/j.jtho.2019.04.018","article-title":"Safety and effectiveness of stereotactic ablative radiotherapy for ultra-central lung lesions: A systematic review","volume":"14","author":"Chen","year":"2019","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ijrobp.2025.01.031_bib0014","doi-asserted-by":"crossref","first-page":"e27","DOI":"10.1016\/j.prro.2015.09.012","article-title":"Fatal complications after stereotactic body radiation therapy for central lung tumors abutting the proximal bronchial tree","volume":"6","author":"Haseltine","year":"2016","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2025.01.031_bib0015","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/j.jtho.2016.03.008","article-title":"Outcomes of hypofractionated high-dose radiotherapy in poor-risk patients with \u201cultracentral\u201d non-small cell lung cancer","volume":"11","author":"Tekatli","year":"2016","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ijrobp.2025.01.031_bib0016","doi-asserted-by":"crossref","first-page":"2819","DOI":"10.2217\/fon-2019-0098","article-title":"Poor survival of non-small-cell lung cancer patients with main bronchus tumor: A large population-based study","volume":"15","author":"Li","year":"2019","journal-title":"Future Oncol"},{"key":"10.1016\/j.ijrobp.2025.01.031_bib0017","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.5858\/arpa.2011-0521-OA","article-title":"Causes of death of patients with lung cancer","volume":"136","author":"Nichols","year":"2012","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.ijrobp.2025.01.031_bib0018","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1186\/s12885-018-4859-7","article-title":"Population-based phase II trial of stereotactic ablative radiotherapy (SABR) for up to 5 oligometastases: SABR-5","volume":"18","author":"Olson","year":"2018","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ijrobp.2025.01.031_bib0019","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/j.ijrobp.2022.05.033","article-title":"Progression-free survival and local control after SABR for up to 5 oligometastases: An analysis from the population-based phase 2 SABR-5 trial","volume":"114","author":"Baker","year":"2022","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2025.01.031_bib0020","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1016\/j.ijrobp.2024.01.008","article-title":"Upfront versus delayed systemic therapy in patients with oligometastatic cancer treated with SABR in the Phase 2 SABR-5 trial","volume":"118","author":"Baker","year":"2024","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2025.01.031_bib0021","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1016\/S1470-2045(19)30718-1","article-title":"Characterisation and classification of oligometastatic disease: A European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation","volume":"21","author":"Guckenberger","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijrobp.2025.01.031_bib0022","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1016\/j.jpedsurg.2010.12.013","article-title":"Location of pulmonary metastasis in pediatric osteosarcoma is predictive of outcome","volume":"46","author":"Letourneau","year":"2011","journal-title":"J Pediatr Surg"},{"key":"10.1016\/j.ijrobp.2025.01.031_bib0023","doi-asserted-by":"crossref","first-page":"5908","DOI":"10.3390\/cancers14235908","article-title":"Survival and prognostic factors of ultra-central tumors treated with stereotactic body radiotherapy","volume":"14","author":"Salvestrini","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ijrobp.2025.01.031_bib0024","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.radonc.2021.03.001","article-title":"Ablative radiotherapy for ultracentral lung cancers: Dosimetric, geometric, and volumetric predictors of outcomes and toxicity","volume":"158","author":"Breen","year":"2021","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2025.01.031_bib0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2023.109697","article-title":"A competing risk analysis of the patterns and risk factors of recurrence in early-stage non-small cell lung cancer treated with stereotactic ablative radiotherapy","volume":"185","author":"Tonneau","year":"2023","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2025.01.031_bib0026","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.lungcan.2005.12.006","article-title":"Differences in clinicopathological and biological features between central-type and peripheral-type squamous cell carcinoma of the lung","volume":"52","author":"Saijo","year":"2006","journal-title":"Lung Cancer"},{"key":"10.1016\/j.ijrobp.2025.01.031_bib0027","first-page":"169","article-title":"Differing histopathology and prognosis in pulmonary adenocarcinoma at central and non ultra-central locations","volume":"8","author":"Moon","year":"2016","journal-title":"J Thorac Dis"},{"key":"10.1016\/j.ijrobp.2025.01.031_bib0028","doi-asserted-by":"crossref","first-page":"e49","DOI":"10.1016\/j.cllc.2016.06.002","article-title":"Primary tumor location is a useful predictor for lymph node metastasis and prognosis in lung adenocarcinoma","volume":"18","author":"Sun","year":"2017","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.ijrobp.2025.01.031_bib0029","first-page":"66","article-title":"Characteristics of lymphovascular metastatic spread in lung adenocarcinoma according to the primary cancer location","volume":"17","author":"Grbi\u0107","year":"2020","journal-title":"Med Glas (Zenica)"},{"key":"10.1016\/j.ijrobp.2025.01.031_bib0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2023.109576","article-title":"Should organs at risk (OARs) be prioritized over target volume coverage in stereotactic ablative radiotherapy (SABR) for oligometastases? A secondary analysis of the population-based phase II SABR-5 trial","volume":"182","author":"Eufemon Cereno","year":"2023","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2025.01.031_bib0031","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1016\/j.ijrobp.2022.01.002","article-title":"Determining planning priorities for SABR for oligometastatic disease: A secondary analysis of the SABR-COMET Phase II randomized trial","volume":"114","author":"Van Oirschot","year":"2022","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2025.01.031_bib0032","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2023.107281","article-title":"Stereotactic body radiotherapy for ultra-central lung tumors: A systematic review and meta-analysis and International Stereotactic Radiosurgery Society practice guidelines","volume":"182","author":"Yan","year":"2023","journal-title":"Lung Cancer"},{"key":"10.1016\/j.ijrobp.2025.01.031_bib0033","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1016\/j.jtho.2021.03.019","article-title":"The HILUS-trial-A prospective nordic multicenter phase 2 study of ultracentral lung tumors treated with stereotactic body radiotherapy","volume":"16","author":"Lindberg","year":"2021","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ijrobp.2025.01.031_bib0034","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s13014-020-01491-w","article-title":"Outcomes of stereotactic body radiotherapy 60\u2009Gy in 8 fractions when prioritizing organs at risk for central and ultracentral lung tumors","volume":"15","author":"Zhao","year":"2020","journal-title":"Radiat Oncol"}],"container-title":["International Journal of Radiation Oncology*Biology*Physics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301625000963?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301625000963?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,21]],"date-time":"2026-06-21T08:32:35Z","timestamp":1782030755000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0360301625000963"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S0360301625000963"],"URL":"https:\/\/doi.org\/10.1016\/j.ijrobp.2025.01.031","relation":{},"ISSN":["0360-3016"],"issn-type":[{"value":"0360-3016","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Impact of Ultracentral Tumor Location on Outcomes in Patients with Pulmonary Oligometastases: A Secondary Analysis of the Single-Arm Phase 2 SABR-5 Trial","name":"articletitle","label":"Article Title"},{"value":"International Journal of Radiation Oncology*Biology*Physics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijrobp.2025.01.031","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}